Engineered polypeptide agents for targeted broad spectrum influenza neutralization

• US 8,637,456 B2
• Filed: 01/27/2011
• Issued: 01/28/2014
• Est. Priority Date: 01/27/2010
• Status: Active Grant

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Sasisekharan, Ram, Viswanathan, Karthik, Soundararajan, Venkataramanan, Raguram, S., Sasisekharan, Viswanathan, Subramanian, Vidya
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): DABKOWSKI, ERINNE R
• Application Number:
  US13/015,455
• Publication Number:
  US 20110201547A1
• Time in Patent Office: 1,097 Days
• US Class Current: 514/3.7
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/162 from virus
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: G01N 2333/11 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: G01N 33/56983 Viruses

Abstract

The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.

Claims

1. An infold agent that binds an hemagglutinin (HA) polypeptide, which infold agent comprises an infold selected from the group consisting of Infold-1, Infold-2, Infold-3, Infold-4, Infold-5, Infold-6, Infold-7, Infold-8, Infold-9, Infold-10, Infold-11, Infold-12, Infold-13, Infold-14, Infold-15, Infold-16, Infold-17, Infold-18, Infold-19, Infold-20, Infold-21, Infold-22, Infold-23, Infold-24, Infold-25, Infold-26, Infold-27, Infold-28, Infold-29, Infold-30, Infold-31, Infold-32, Infold-33, Infold-34, Infold-35, Infold-36, Infold-37, Infold-38, Infold-39, and Infold-40.

2. The infold agent of claim 1, wherein the infold agent comprises Infold-3.

3. The infold agent of claim 1, wherein the infold agent comprises Infold-28.

4. A pharmaceutical composition comprising:

an infold agent of claim 1 and a pharmaceutically acceptable carrier.

7. A method of treating influenza A virus subtype H1N1 or H3N2 in a subject comprising administering to the subject the pharmaceutical composition of claim 4, wherein the subject has been exposed to an infected source selected from the group consisting of avian, human, swine and combinations thereof.

8. The method of claim 7, comprising administering the pharmaceutical composition in combination with one or more other pharmaceutical agents.

5. An infold agent that binds an HA polypeptide, which infold agent comprises Infold-22.

6. A pharmaceutical composition comprising:

the infold agent of claim 5 and a pharmaceutically acceptable carrier.